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Editor: D. BarceloFish can be exposed to a variety of neuroactive pharmaceuticals via the efﬂuent discharges from wastewater
treatment plants and concerns have arisen regarding their potential impacts on ﬁsh behaviour and ecology. In
this study, we investigated the uptake of 14 neuroactive pharmaceuticals from a treated wastewater efﬂuent
into blood plasma and brain regions of roach (Rutilus rutilus) after exposure for 15 days.We show that a complex
mixture of pharmaceuticals including, 6 selective serotonin reuptake inhibitors, a serotonin-noradrenaline reup-
take inhibitor, 3 atypical antipsychotics, 2 tricyclic antidepressants and a benzodiazepine, concentrate in different
regions of the brain including the telencephalon, hypothalamus, optic tectum and hindbrain of efﬂuent-exposed
ﬁsh. Pharmaceuticals, with the exception of nordiazepam, were between 3–40 fold higher in brain compared
with blood plasma, showing these neuroactive drugs are readily uptaken, into brain tissues in ﬁsh. To assess
for the potential for any adverse ecotoxicological effects, the effect ratio was calculated from human therapeutic
plasma concentrations (HtPCs) and the measured or predicted ﬁsh plasma concentrations of pharmaceuticals.
After accounting for a safety factor of 1000, the effect ratios indicated that ﬂuoxetine, norﬂuoxetine, sertraline,
and amitriptyline warrant prioritisation for risk assessment studies. Furthermore, although plasma concentra-
tions of all the pharmaceuticalswere between 33 and 5714-fold belowHtPCs, alterations in serotonin, glutamate,
acetylcholine and tryptophan concentrations were observed in different brain regions of efﬂuent-exposed ﬁsh.
This study highlights the importance of determining the potential health effects arising from the concentration
of complex environmental mixtures in risk assessment studies.
© 2017 Elsevier B.V. All rights reserved.Keywords:
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native form or as metabolites and they enter aquatic systems mainly
via efﬂuents from wastewater treatment works (WwTWs) (Fent et al.,
2006; Gardner et al., 2012; Kostich et al., 2014; Petrie et al., 2015;
Tanoue et al., 2015). Recently, concerns have arisen regarding the pres-
ence of neuroactive pharmaceuticals, such as selective serotonin reup-
take inhibitors (SSRIs) and benzodiazepines, in WwTW efﬂuents
because these pharmaceuticals have been shown to alter behaviour of
different ﬁsh species under experimental laboratory conditions
(Brodin et al., 2013; Huerta et al., 2016; Margiotta-Casaluci et al.,
2014; Valenti et al., 2012). In addition to SSRIs, other types of antide-
pressants including serotonin-noradrenaline reuptake inhibitors
(SNRIs) and tricyclic antidepressants are also regularly detected in efﬂu-
ents fromWwTWs (Grabicova et al., 2014; Lajeunesse et al., 2011; Petrie
et al., 2015). In comparison to SSRIs, the effects of tricyclic antidepres-
sants on ﬁsh behaviour have been less studied, but a member of this
class, amitriptyline, is extensively prescribed in England to treat depres-
sion and psychiatric disorders (N10,000 kg in England in 2012) (Petrie
et al., 2015; Ziarrusta et al., 2017).
Recent studies investigating the effects of neuroactive pharmaceuti-
cals on ﬁsh have focused on behavioural endpoints as these are likely to
be the primary effects of exposure to neuroactive pharmaceuticals ac-
cording to the read-across hypothesis (Margiotta-Casaluci et al., 2014;
Valenti et al., 2012). This hypothesis has been suggested to be a useful
tool in risk assessment studies and is based on the theory that blood
plasma concentrations of pharmaceuticals in non-target vertebrates
similar to human therapeutic plasma concentrations are likely to
cause pharmacological effects in organisms such as ﬁsh (Huggett et al.,
2003; Rand-Weaver et al., 2013). However, there is uncertainty as to
whether environmental water concentrations of neuroactive drugs
such as SSRIs bioconcentrate to high enough concentrations in the plas-
ma or target tissues to cause behavioural effects in ﬁsh (Sumpter et al.,
2014). Mean measured concentrations of neuroactive pharmaceuticals
in WwTW efﬂuents have been reported at between 1 and 330 ng/L for
SSRIs (e.g., ﬂuoxetine, sertraline and citalopram), SNRIs (venlafaxine),
tricyclic antidepressants (amitriptyline) and benzodiazepines (diaze-
pam) (Grabicova et al., 2014; Petrie et al., 2015), and these are far
below water concentrations for SSRIs ﬂuoxetine, sertraline and
citalopram (in the range of 1–116 μg/L) and for venlafaxine (between
250 and 500 μg/L) reported to affect the behaviour of different ﬁsh spe-
cies in laboratory experiments (Bisesi et al., 2014; Kellner et al., 2016;
Margiotta-Casaluci et al., 2014; Valenti et al., 2012; Xie et al., 2015). In
contrastwith these reports however, there have been some studies indi-
cating that ﬂuoxetine at concentrations below 1 μg/L (0.3 μg/L and 0.54
μg/L), and therefore similar to environmental concentrations, could af-
fect ﬁsh behaviour (Barry, 2013; Dzieweczynski and Hebert, 2012). Fur-
thermore, non-monotonic shifts in behavioural responses have been
reported for neuroactive compounds such as oxazepam (Huerta et al.,
2016).More information is needed on the uptake and tissue partitioning
of mixtures of neuroactive pharmaceuticals in ﬁsh to support the envi-
ronmental risk assessments of these drugs in aquatic environments.
In a recent study, we used a holistic untargeted chemical proﬁling
approach to identify pharmaceuticals accumulating in roach (Rutilus
rutilus) exposed to a treated wastewater efﬂuent. We identiﬁed 14 dif-
ferent neuroactive compounds in extracts of either gonad, liver, gills,
kidney or plasma (David et al., 2017). The aim of the study presented
here was to use targeted analyses to quantify the concentrations of
this pharmaceutical mixture in plasma and brain and investigate for bi-
ological responses in the brain via measurement of neurotransmitter
concentrations as a consequence of efﬂuent exposure. We provide
novel information on the accumulation pattern of neuroactive pharma-
ceuticals in four different regions of the brain, i.e. the telencephalon, hy-
pothalamus, optic tectum and hindbrain. We show that even though
plasma concentrations of all neuroactive drugs were well below thehuman therapeutic plasma concentrations, concentrations of neuro-
transmitters were altered in the hypothalamus of efﬂuent-exposed
ﬁsh, highlighting the need to understand the effects of exposure to com-
plex chemical mixtures on ﬁsh behaviour and physiology.
2. Materials and methods
2.1. Chemicals and reagents
Certiﬁed standards of glutamate, acetylcholine, serotonin, trypto-
phan, ﬂuoxetine (Fluo), sertraline (Ser), paroxetine (Par), clozapine
(Clo), venlafaxine (Venlaf), and also formic acid, ammoniumhydroxide,
phosphoric acid were obtained from Sigma Aldrich, Dorset, UK.
Norﬂuoxetine (norFluo), norsertraline (norSer), citalopram (Cit),
norclozapine (norClo), quetiapine (Quet), amitriptyline (Ami),
noramitriptyline (norAmi), diazepam (Diaz), nordiazepam (norDaz),
serotonin-d4, norﬂuoxetine-d6 were purchased from LGC standards
UK. Venlafaxine-d6,ﬂuoxetine-d5were purchased fromQMX Laborato-
ries Limited UK. All standards were N99% compound purity and deuter-
ated standards N97% isotopic purity. HPLC grade acetonitrile, methanol
andwaterwere obtained from Rathburns UK. Oasis HLB cartridges (1 g)
were obtained from Waters, Manchester, UK and Strata-X-C Polymeric
Reversed Phase 96-Well Plates (33 μm sized particles, 30 mg/well)
from Phenomenex, Macclesﬁeld UK.
2.2. Fish exposure and sample collections
A population of male and female sexually mature roach (Rutilus
rutilus, age 2+, mean ± SEM length of 14.5 ± 1.3 cm and weight 45.4
± 12.1 g) was exposed for 15 days to either a treated efﬂuent from a
WwTW or to clean water for the control population (60 ﬁsh per treat-
ment and 120 ﬁsh in total). TheWwTW received 95% inﬂuent from do-
mestic sources (population equivalent of 117,574) and 5% input from
industrial wastewaters. The inﬂuent was treated by ﬁne screens, chem-
ically assisted settlement, biological aerated ﬂooded ﬁlter processes and
ultraviolet disinfection. The pH of the efﬂuentwas 7.3, concentrations of
suspended solids 21mg/L, biochemical oxygen demand 11mg/L, chem-
ical oxygen demand 67mg/L and total ammonia 29mg/L during the ex-
posure period (South West Water data). Roach were exposed in
triplicate tanks (20 ﬁsh per 200 L tank) to either dechlorinated water
or 100% ﬁnal efﬂuent for ﬁfteen days. The ﬂow rate was 10 L/min and
the efﬂuent and water was continually aerated. The ﬁsh were main-
tained at an average temperature of 12 ± 1 °C for both treatments
under a constant photo-period (15 h light: 9 h dark).
After 15 days, ﬁsh were terminated using an overdose of
phenoxyethanol and according to UK Home Ofﬁce regulations and
local ethical guidelines. Blood was collected from the caudal vein
using heparinised needles (BD Microlance 3 25G 0.5 × 25 mm), centri-
fuged (5 min, 10,000 g) and the plasma supernatant stored at−70 °C.
Four different parts of the brain, i.e. the telencephalon, the hypothala-
mus, the optic tectum and the hindbrain were carefully dissected and
immediately snap frozen in liquid nitrogen. All samples were stored at
−70 °C until analysis.
Wastewater efﬂuent samples (2 × 2.5 L) were collected in solvent
washed, acid rinsed amber glass bottles at the beginning of the ﬁsh ex-
posure (day 0), after 7 days, and at the end of the exposure period (day
15) in order to monitor the concentrations of neuroactive pharmaceuti-
cals in the wastewater efﬂuent throughout the exposure period. Sam-
ples were stored at 4 °C with the addition of acetic acid (1%) and
methanol (5%) and were extracted within 12 h after collection.
2.3. Sample preparation
2.3.1. Brain tissues and plasma samples
Telencephalon (mean± standard deviation; 18 ± 4 mg), hypothal-
amus (15 ± 3 mg), hindbrain (56 ± 8 mg) and optic tectum (80 ±
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and using a Microson XL2000 ultrasonic probe (Misonix Farmingdale)
(10W × 40 s). Before extraction, the mix of internal standards (IS) (se-
rotonin-d4, venlafaxine-d6, ﬂuoxetine-d5 and norﬂuoxetine-d6) was
added to each tissue sample. The amount of IS added were adjusted to
the initial mass of tissue used so that the amount of each IS
corresponded to 1.5 ng/18 mg of telencephalon, 1.5 ng/15 mg of hypo-
thalamus, 1.5 ng/50 mg of hindbrain and 1.5 ng/75 mg of optic tectum.
After extraction, samples were transferred to clean centrifuge tubes,
centrifuged (13,000 RCF, 10 min) and the supernatant collected. After
addition of 1500 μL of ultra pure water and 36 μL of phosphoric acid,
the samples were puriﬁed using the Strata-X-C SPE plates. Sorbents
were conditioned with 1 mL methanol, equilibrated with 1 mL of 2%
phosphoric acid in HPLC grade water prior to loading brain extracts
onto the SPE wells. After a washing step using 1 mL HPLC grade water,
sorbents were dried under vacuum for 15 min. Analytes were eluted
with 1mL of 5% ammonium hydroxide inmethanol. Eluates were evap-
orated to dryness, reconstituted in 50 μL of 80/20 water/methanol (v/v)
and stored at−20 °C until analysis.
Plasma concentrations of the pharmaceuticalsweremeasured for fe-
male ﬁsh where more volume of blood sample was available for chem-
ical analyses. Plasma samples (150 μL)were spikedwith 1 ng of themix
of IS and 300 μL of methanol and themixture vortexed (1min) and cen-
trifuged (13,000 RCF, 10min). The supernatantwas collected, 1500 μL of
HPLCwater and 36 μL of phosphoric acid were added and samples were
puriﬁed using the Strata-X-C plates as described previously,
reconstituted in 50 μL of 80/20 water/methanol (v/v) and stored at
−20 °C until analysis.
2.3.2. Wastewater efﬂuent
For each sample, one litre of wastewater containing 5% of methanol
and 1% of acid acetic and spiked with the mix of IS was pre-ﬁltered
through glass wool and ﬁlter paper Whatman No1 (Whatman, Maid-
stone, UK). Samples were then extracted through an Oasis HLB
(20mL, 1 g) cartridge, which was pre-conditioned with 10mL of meth-
anol and 10 mL HPLC water. The cartridge was washed with 20 mL of
distilled water and dried under vacuum. Analytes were eluted with
10 mL of methanol and 10 mL of ethyl acetate. Extracts were dried
and reconstituted in 1 mL of methanol. 300 mL of the residue was puri-
ﬁed using Strata-X-C plates described above and reconstituted to a ﬁnal
volume of 120 μL (80/20 water/methanol (v/v)) and stored at−20 °C
until analysis.
2.4. UHPLC-ESI-MS/MS
UHPLC-MS/MS analyses were carried out using a Waters Acquity
UHPLC system coupled to a Quattro Premier triple quadrupole mass
spectrometer from Micromass (Waters, Manchester, UK). Samples
were separated using a reverse phase Acquity UHPLC BEH C18 column
(1.7 μm, 2.1 mm × 100 mm, Waters, Manchester, UK) ﬁtted with a
ACQUITY UHPLC BEH C18 VanGuard pre-column (130 Å, 1.7 μm,
2.1 mm × 5 mm, Waters, Manchester, UK) and maintained at 22 °C. In-
jection volume was 20 μL and mobile phase solvents were 94.8% water,
5% ACN, 0.2% formic acid (A) and 99.8% ACN, 0.2% formic acid (B). Sep-
arationwas achieved using a ﬂow rate of 0.1mL/minwith the following
A:B gradient; 100:0 to 64:36 in 6 min; from 64:36 to 20:80 at 15 min,
from 20:80 to 100% B at 15.01 min and held for 5 min prior to return
to initial conditions and equilibration for 5 min.
MS/MS was performed in the multiple reaction monitoring (MRM)
using ESI in the positive mode. Two characteristic fragmentations of
the protonatedmolecular ion [M+H]+weremonitored (one for quan-
tiﬁcation and the other one for conﬁrmation). The declustering poten-
tial and collision energy were optimised for each analyte (Table S1).
Other parameters were optimised as follows: capillary voltage
−3.3 kV, extractor voltage 8 V,multiplier voltage 650 V, source temper-
ature 100 °C, desolvation temperature 300 °C. Argon was used ascollision gas (P collision cell: 3 × 10−3 mbar), and nitrogen was used
as desolvation gas (600 L/h). Data were acquired using MassLynx 4.1
and the quantiﬁcationwas carried out by calculating the response factor
of neurotransmitters and pharmaceuticals to their respective IS. Con-
centrations were determined using a least-square linear regression
analysis of the peak area ratio versus the concentration ratio of the an-
alyte to the IS. In order to account for interferences with thematrix, cal-
ibration curves for the pharmaceuticals present in brain tissues and
plasma analyses were made in the sample matrix using plasma and
brain tissues collected from additional unexposed ﬁsh. A minimum of
a six point calibration curve (R2 N 0.99) was used to cover the range of
concentrations observed in the different matrices, within the linear
range of the instrument. Calibration curves were prepared in solvent
only to quantify neurotransmitters as these were naturally occurring
at high concentrations in all brain tissues and not subject to matrix in-
terference. Method detection and quantiﬁcation limits (MDL and MQL,
respectively) were determined from spiked samples which had been
extracted using the Strata-X-C method. MDLs were determined as the
minimum amount of analyte detected with a signal-to-noise ratio of 3
and MQLs as the minimum amount of analyte detected with a signal-
to-noise ratio of 10 (Table S2).
2.5. Plasma and brain bioconcentration factors
For the purpose of our study, we deﬁned plasma and brain
bioconcentration factors (BCFs) of pharmaceuticals as the ratio of
blood plasma or brain to water concentrations for the speciﬁed expo-
sure time adopted (i.e. 15 days) for whichwewould expect equilibrium
saturation to have been reached, based on studies in other freshwater
ﬁsh such as Japanese medaka and channel catﬁsh where equilibrium
concentrations for ﬂuoxetine (Paterson and Metcalfe, 2008) and for di-
azepam (Overturf et al., 2016) were reached within 2–3 days of expo-
sure. BCFs were calculated as follows:
BCF ¼ Cplasma or brain=Cambient water
where Cplasma or brain andCambient water are the chemical concentrations in
plasma or brain of ﬁsh and in ambient water (i.e., the WwTW efﬂuent),
respectively. Cplasma and Cambient water were both expressed in ng/mL
while Cbrain was expressed in ng/g (wet weight). Cambient water was cal-
culated from the mean concentration of the 3 sampling time points
(day 0, 7 and 15 days of the ﬁsh exposure period) and Cplasma and Cbrain
were calculated from the average concentrations measured in plasma
and the four parts of the brain respectively. To calculate the average
concentrations measured in the four parts of the brain of the efﬂuent-
exposed ﬁsh, the total amount found in the four parts of the brain was
ﬁrst calculated and then divided by the total mass of brain tissues
analysed for each individual ﬁsh.
Predicted BCFplasma, were calculated using ﬁsh steady-state plasma
concentration (FssPC) which can be predicted using the Fish Plasma
Model as follows (Huggett et al., 2003):
FssPC ¼ water concentration;ng=mL½   Pb=w
Pb/w corresponds to blood to water partition coefﬁcient and can be
calculated using the following equation:
Log Pb=w ¼ 0:73 Log D7:4–0:88
In the last equation, Log D7.4 (i.e., Log D value at buffer pHof 7.4)was
used instead of Log Kow as several studies have shown that the ambient
pH signiﬁcantly affects the ionization of the pharmaceuticals analysed
in this study (Margiotta-Casaluci et al., 2014; Nallani et al., 2016;
Tanoue et al., 2015; Valenti et al., 2009). Log D7.4 were obtained from
chemspider (http://www.chemspider.com/).
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One workup sample (i.e. extraction using extraction methods with-
out a tissue/plasma sample) per batch of 12 sampleswas injected on the
UHPLC-MS/MS at the beginning of the run to ensure that no contamina-
tion occurred during the sample preparation. Solvent samples
(methanol:water, 20:80) were also injected between sample batches
to rule out the possibility of any carryover in the UHPLC system that
might affect adjacent results in analytical runs. Identities of detected
neurotransmitters and pharmaceuticals were conﬁrmed by comparing
ratios of MRM transitions in samples with that of pure standards. Qual-
ity control samples (QCs, i.e., standard solutions) were injected before
all sample batches to monitor sensitivity changes and every 12 samples
tomonitor the sensitivity changes during the analysis of each batch. Re-
covery experiments performed on spiked brain tissues (50 ng/g, n= 4),
plasma samples (10 ng/mL, n = 4) and HPLC water (8.5 ng/mL, n = 4)
gave absolute recovery values ranging from 61 ± 7 to 107 ± 14% for
neurotransmitters and pharmaceuticals (Table S3). None of the studied
pharmaceuticals were detected in the samples from control ﬁsh.
2.7. Statistical analysis
All statistical analyses were carried out using GraphPad Prism 5 soft-
ware. To compare pharmaceutical and neurotransmitter concentrations
in males and females between treatments, 12 ﬁsh per treatment were
analysed by taking randomly 4 ﬁsh (2 males and 2 females) from each
triplicate tank (n = 3 for biological replicates per treatment and n =
12 for analytical replicates). Data was tested for normality using the
Shapiro-Wilk test. Differences in pharmaceutical concentrations be-
tween efﬂuent-exposed males and females in different parts of the
brainwere assessed by two-way analysis of variance (ANOVA) followed
by a Bonferronì multiple comparison tests. One-way ANOVA followed
by Bonferronì multiple comparison tests were used to compare phar-
maceutical concentrations in the different parts of the brain of
efﬂuent-exposed male or female ﬁsh. Nonparametric Mann-Whitney
(M-W) U tests were used to compare neurotransmitter concentrations
between control and exposedmales and females. Differenceswere con-
sidered statistically signiﬁcant at p ≤ 0.05. Statistical results for the dif-
ferent tests, including the value of the test, the degrees of freedom,
and the p-values are provided in Table S5 (two-way ANOVA), S6
(one-way ANOVA, male), S7 (one-way ANOVA, female) and S9
(Mann–WhitneyU tests). To perform the statistical analyses, all concen-
trations that were over the limits of detection (≥MDL) but below the
limits of quantiﬁcation (bMQL) were assigned the value considered as
the MDL in each case. Concentrations below the MDL were considered
to be zero.
3. Results and discussion
3.1. Concentrations of neuroactive pharmaceuticals in wastewater of
efﬂuent-exposed roach after 15 days of exposure
Thirteen of the 14 test pharmaceuticals (norclozapine excluded)
were detected in theWwTW efﬂuent sampled during the exposure pe-
riod (Table 1). Mean concentrations ranged from 8.5± 1.1 ng/L (parox-
etine) to 374 ± 44 ng/L (amitriptyline). Individual pharmaceutical
concentrations measured in the WwTW efﬂuent during the exposure
period were in the same range as that reported in other WwTW efﬂu-
ents in the UK (i.e., between 10 and 500 ng/L) (Petrie et al., 2015). For
example, mean concentrations of ﬂuoxetine in our study were 62 ±
5.6 ng/L compared with a median of 23 ng/L and 95 percentile of
69 ng/L for ﬂuoxetine measured in a comprehensive study of 162
WwTW efﬂuents in the UK (Gardner et al., 2012). Likewise, mean con-
centrations of norﬂuoxetine (37 ± 13 ng/L), venlafaxine (356 ±
39 ng/L) and amitriptyline (374 ± 44 ng/L) in our study aligned with
those measured in several other UK WwTW efﬂuents (Petrie et al.,2015) indicating that our study efﬂuent content of neuroactive pharma-
ceuticals was representative of UK WwTW efﬂuents more widely.
The detection of mixtures of SSRIs and other neuroactive com-
pounds in WwTW efﬂuents is of potential environmental concern be-
cause they have the potential to alter ﬁsh behaviour (Brodin et al.,
2013; Margiotta-Casaluci et al., 2014; Valenti et al., 2009). However,
concentrations of the SSRIs ﬂuoxetine, sertraline and citalopram and
the SNRI venlafaxine measured in the undiluted efﬂuent in our study
werewell belownominal concentrations that have been shown to affect
ﬁsh behaviour under experimental laboratory conditions. For instance,
exposure to water concentrations of sertraline at N3 μg/L were neces-
sary to cause changes in shelter-seeking behaviour in adult male fat-
head minnows (Valenti et al., 2012) and shoaling activity in crucian
carp (Xie et al., 2015). Similarly, other studies investigating the effects
of exposure to ﬂuoxetine, citalopram or venlafaxine have shown that
behaviour-related changes in ﬁsh were only observed after exposure
to concentrations in the μg/L range (Bisesi et al., 2014; Kellner et al.,
2016;Margiotta-Casaluci et al., 2014). In contrast to a number of studies
investigating exposure effects of SSRIs on ﬁsh behaviour, little is known
on the potential behavioural effects of exposure to atypical antipsy-
chotics such as clozapine or tricyclic antidepressants such as amitripty-
line. In addition, risk assessment studies are based on exposures to
single chemicals and do not reﬂect the complex and diverse mixtures
of neuroactive pharmaceuticals that ﬁsh are exposed to in WwTW con-
taminated waters as revealed in our study.
3.2. Concentrations of neuroactive pharmaceuticals in plasma and brain of
efﬂuent-exposed roach
After a 15 day exposure to WwTW efﬂuent, 11 of the 14 test com-
pounds were detected in plasma, the exceptions being paroxetine,
norclozapine and diazepam. No analytes were detected in plasma
from control ﬁsh (Table 1). Citalopram, clozapine and quetiapine and
noramitriptyline were present at concentrations below the MQL.
Mean measured concentrations of all other analytes were between
0.07 ± 0.02 (venlafaxine) and 9.5 ± 4.7 ng/mL (norsertraline). For the
analytes where plasma concentrations were above the MQL, the mea-
sured BCFsplasma ranged from 0.2 to 37, in agreement with the BCFplasma
values for SSRIs and venlafaxine from a previous exposure study in
which rainbow trout were exposed to an undiluted (Swedish) WwTW
efﬂuent for 13 days (Grabicova et al., 2014). In our study, the measured
BCFswere in the same order ofmagnitude but differed by between 2- to
7-fold lower or higher compared to their predicted BCFplasma values
(Table 1). A previous study (Margiotta-Casaluci et al., 2014) has report-
ed an inter-individual variability up to 7.6-fold in drug uptake (water/
plasma), which would suggest that the differences between measured
and predicted BCFs in our study are within an acceptable level of accu-
racy. Possible reasons for the discrepancies betweenmeasured and pre-
dicted BCFplasma values for these pharmaceuticals, as well as for other
xenobiotics, may involve water pH (Valenti et al., 2009), routes of expo-
sure other than via diffusion through the gills (e.g., the diet), the effects
of uptake/elimination mechanisms at gill membranes, plasma protein
binding, and/or hepatic clearance rates (Tanoue et al., 2015).
Analysis of brain tissues of roach after a 15 day exposure to WwTW
efﬂuent revealed that 13 neuroactive pharmaceuticals were detected in
the optic tectum, 11 in the hindbrain and 10 in both the telencephalon
and the hypothalamus (Fig. 1, Table S4). None of the pharmaceuticals
were detected in brain regions of control ﬁsh. Diazepamwas not detect-
ed in any of the brain tissues of efﬂuent-exposed ﬁsh and its biologically
active metabolite nordiazepam was only detected in the optic tectum
but at concentrations below the MQL. Both diazepam and nordiazepam
are rapidly metabolized in vertebrate tissues (Friedman et al., 1986)
which may account for the low levels present in brain and plasma de-
spite being present at a concentration of 19 ± 6 ng/L ng/L (mean ±
SD) in the efﬂuent. The highest concentrations of pharmaceuticals de-
tected in brain tissues of male and female roach were norsertraline
Table 1
Pharmaceutical concentrations in wastewater efﬂuent and bioconcentration factors (BCFs) in efﬂuent-exposed ﬁsh.
[Efﬂuent] [Fish plasma] BCFplasma BCFbrain [Brain]/[plasma]
Pharmaceuticals Range (ng/L) Av ± SD (ng/L) Range (ng/mL) Av ± SD (ng/mL) Measured Predicted Measured
SSRIs
Fluoxetine 54–72 62 ± 5.6 0.33–0.45 0.39 ± 0.04 6.3 2.5 68 9.7
Norﬂuoxetine 17–61 37 ± 13 0.43–0.83 0.53 ± 0.15 14 5.6 285 18
Sertraline 47–65 55 ± 5.6 0.5–1 0.76 ± 0.21 14 26 361 27
Norsertraline 215–311 260 ± 31 3.3–15 9.5 ± 4.7 37 15 1581 37
Citalopram 211–340 274 ± 39 b0.02a–b0.05b n.a. n.a. n.a. 1.6 n.a.
Paroxetine 6.6–9.8 8.5 ± 1.1 b0.17a n.a. n.a. n.a. 67 n.a.
Atypical antipsychotics
Clozapine 20–30 25 ± 3.5 b0.07a–b0.2b n.a. n.a. n.a. 105 n.a.
Norclozapine b0.08a b0.33a n.a. n.a. n.a. n.a. n.a.
Quetiapine 18–33 23 ± 6.2 b0.03a–b0.1b n.a. n.a. n.a. 157 n.a.
Tricyclic antidepressants
Amitriptyline 298–421 374 ± 44 0.90–2.2 1.5 ± 0.5 4.0 19 15 4.4
Noramitriptyline 31–49 43 ± 7.6 b0.20b–0.3 0.16 ± 0.1 3.7 6.1 42 14
SNRI
Venlafaxine 295–393 356 ± 39 0.03–0.1 0.07 ± 0.02 0.2 1.5 0.7 3.7
Benzodiazepines
Diazepam 10–26 19 ± 6.2 b0.02a n.a. n.a. n.a. n.a. n.a.
Nordiazepam 56–96 77 ± 15 b0.50b–0.55 0.51 ± 0.01 6.6 9.3 2 0.31
Wastewater efﬂuentswere sampled at the beginning of the experiment, after 7 days and the end of the experiment. Sampleswere analysed in triplicates for each sampling point (n=9 in
total). BCFbrain was calculated from the sum of concentrations measured in the brain regions. a = MDL values; b = MQL values, SD = standard deviation and n.a. not applicable as con-
centrations in efﬂuent, plasma or brain extracts were bMQL. For mean calculations, concentrations that were over the limits of detection (≥MDL) but below the limits of quantiﬁcation
(bMQL) were assigned the MDL value. Concentrations below the MDL were considered to be zero.
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Fig. 1. Concentrations of neuroactive pharmaceuticals (ng/g; mean ± standard deviation) in the telencephalon (A), hypothalamus (B), optic tectum (C) and hindbrain (D) of efﬂuent-
exposed male and female ﬁsh. Brain tissue from 12 ﬁsh (6 males and 6 females) sampled from three replicate tanks (2 males and 2 females per tank) were analysed. None of the
studied pharmaceuticals were detected in the control ﬁsh. * signiﬁcant difference between male and female ﬁsh p ≤ 0.05. Fluo = ﬂuoxetine, norFluo = norﬂuoxetine, sertraline, norSer
= norsertraline, Cit = citalopram, Par = paroxetine, Clo = clozapine, norClo = norclozapine, Quet = quetiapine, Ami = amitriptyline, norAmi = noramitriptyline, Venlaf =
venlafaxine, Diaz = diazepam, norDaz = nordiazepam.
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Table 2
Human therapeutic plasma concentrations (HtPC) and effect ratio of analysed
pharmaceuticals.
HtPCa Effect ratio ﬁsh plasmab
Pharmaceuticals ng/mL Measured Predicted
SSRIs
Fluoxetine 100–500 256–1282 646–3229
Norﬂuoxetine 150–400 283–755 724–1932
Sertraline 30–250 39–329 21–176
Norsertraline Unknown – –
Citalopram 10–200 N500–10,000c 32–645
Paroxetine 10–70 nd –
Atypical antipsychotics
Clozapine 300–800 N4286–10,000c 938–2500
Norclozapine 100–300 nd –
Quetiapine 20–500 N667–16,667c 143–3571
Tricyclic antidepressants
Amitriptyline 50–300 33–200 7–42
Noramitriptyline 60–300 375–1875 231–1154
SNRI
Venlafaxine 30–400 429–5714 58–770
Benzodiazepines
Diazepam 200–2000 nd –
Nordiazepam 20–800 39–1569 28–1121
a HtPC were obtained from Regenthal et al. (1999) and Schulz et al. (2012).
b Effect ratio was calculated as HtPC/Cplasma, where Cplasma in ﬁsh was an average of the
measured values in the plasma or the predicted values from mean concentrations mea-
sured in the ambientwastewater efﬂuent. The range of effect ratios are based on the range
of published HtPC values.
c Based on Cplasma MDL value when plasma concentrations were between MDL and
MQL. nd = not detected (i.e. concentrations bMDL).
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in the optic tectum), norﬂuoxetine (14±2.5 ng/g in the telencephalon),
norclozapine (9.4 ± 5.8 ng/g in the hindbrain), amitriptyline (7.5 ±
2.7 ng/g in the hindbrain), and ﬂuoxetine (5.7 ± 4 ng/g in the hind-
brain) (Table S4). Mean concentrations of citalopram, paroxetine,
venlafaxine and nordiazepamwere ≤1 ng/g in all brain tissues. Paroxe-
tine and nordiazepamwere detected only in the optic tectum and not in
other brain tissues. This wasmost likely because the greater mass of tis-
sue available for the analysis of the optic tectum thatwas on average 1.4,
4.4 and 5.3 times higher than for the hindbrain, the telencephalon and
the hypothalamus, respectively, thus inﬂuencing the MDL. Likewise,
theMDL for norclozapine was higher than that of the other compounds
(Table S2) whichmay explain why it was only detected in the optic tec-
tum and the hindbrain.
These ﬁndings are in agreement with reports that ﬂuoxetine, sertra-
line and their “nor”metabolites are common SSRIs detected in the brain
of ﬁsh species collected in an efﬂuent-dominated stream inUSA (Brooks
et al., 2005), in the brain of carp collected in an efﬂuent-dominated river
in Japan (Tanoue et al., 2015) and in the brain of brook trout exposed to
a diluted efﬂuent from a WwTW in Canada (Lajeunesse et al., 2011).
Sertraline, as well as citalopram and venlafaxine were also detected in
the brain of rainbow trout exposed to an undiluted WwTW efﬂuent in
Sweden (Grabicova et al., 2014) and the antidepressant bupropion
and the antipsychotic risperidone have been found to accumulate in
the brain of round goby exposed to undiluted WwTW efﬂuents in
Canada (McCallum et al., 2017). Here we show that other neuroactive
drugs including the antipsychotics clozapine, norclozapine and
quetiapine as well as the tricyclic antidepressants amitriptyline and its
‘nor’ metabolite also bioaccumulate in ﬁsh brain together with SSRIs
and venlafaxine.
Accumulation of pharmaceuticals in the brain of efﬂuent-exposed
ﬁsh was not affected by sex except for norsertraline which was present
at slightly higher concentrations (1.2–1.7-fold) inmales comparedwith
females in the telencephalon, hypothalamus and optic tectum (p b 0.05)
but not in the hindbrain (Fig. 1). Generally, proﬁles of the pharmaceuti-
cals were similar between the different regions of the brain of efﬂuent
exposed ﬁsh. Direct comparison of the distribution of sertraline,
norsertraline, norﬂuoxetine and quetiapine between brain regions
was possible as they were present at concentrations above the MQL in
all four brain regions. However, quetiapine concentrations in both
sexes were signiﬁcantly higher in the optic tectum, sertraline and
norsertraline were generally lower in the telencephalon and
norﬂuoxetine (females only) signiﬁcantly higher in the telencephalon
compared with other brain regions (p b 0.05, See Figs. S1 and S2). The
relatively uniform concentrations of SSRIs in different regions of the
human brain after autopsy has been reported previously indicating
that there are little regional differences in their uptake and metabolism
between brain compartments (Wille et al., 2009). The ratios of concen-
trations of the demethylated ‘nor’ metabolites to the parent compound
were measured for ﬂuoxetine, sertraline and amitriptyline in the efﬂu-
ent samples and were close to the values reported in human plasma
(Table S8). However, the same ratios measured in ﬁsh plasma and
brain regions were consistently higher for ﬂuoxetine and sertraline
compared with the efﬂuent indicating further metabolism to the ‘nor’
metabolite within the ﬁsh tissues.
The measured BCFbrain values of pharmaceuticals in the summed
brain regions were 3–40 fold higher than measured BCFsplasma and
ranged from 0.7 for venlafaxine to 1581 for norsertraline, indicating ef-
ﬁcient transport and uptake into brain tissues. Similar BCFbrain values
and brain/plasma concentration ratios of SSRIs have been reported in
ﬁsh exposed to WwTW efﬂuents (Grabicova et al., 2014; Lajeunesse et
al., 2011; Tanoue et al., 2015). In our study, compounds such as paroxe-
tine, clozapine and quetiapine did not bioconcentrate in the plasma
(BCFs b 1), but these compounds were quantiﬁed at higher concentra-
tions in the brain with BCFs between 67 and 157. Our data emphasise
the importance of analysing target tissues of pharmaceuticals wherethere is a greater potential for bioaccumulation compared with the
ﬁsh blood plasma.
3.3. The effect ratio (ER)
Comparison of ﬁsh plasma levels with human therapeutic plasma
concentrations (HtPCs) has been proposed as a technique to estimate
the potential hazards of pharmaceuticals in wild ﬁsh (Huerta et al.,
2016; Margiotta-Casaluci et al., 2014; Tanoue et al., 2015). The read-
across hypothesis has been proposed as a ﬁrst step to study the poten-
tial for adverse ecotoxicological effects due to exposure to environmen-
tal pharmaceuticals and remains to be proven for most biologically
active compounds (Huggett et al., 2003; Rand-Weaver et al., 2013).
The ER was calculated from a range of HtPCs measured in human sam-
ples (Regenthal et al., 1999; Schulz et al., 2012) and the measured or
predicted ﬁsh plasma concentrations of pharmaceuticals (Table 2). An
ER ≤ 1 indicates that the predicted drug concentration in the ﬁsh plasma
is equal to or greater than the drug concentration in human plasma that
elicits a therapeutic effect. Measured ER values (i.e., based on measured
plasma concentrations) were generally similar to predicted values and
ranged from 33–5714 for all compounds, and were between 39–1282
for SSRIs. In addition, combined ERs were calculated for the 3 SSRIs ser-
traline,ﬂuoxetine andnorﬂuoxetine by assuming an additive effect. Ser-
traline being the most potent, was used as the reference and relative
potencies of ﬂuoxetine and norﬂuoxetine to sertraline were calculated
based on respective HtPCs. The calculated combined ER values for
these 3 compounds ranged from 31 to 195. Norsertraline was not con-
sidered in thismixture as it has only 5–10% of the serotonin reuptake in-
hibitor potency of sertraline and therefore a minimal contribution to
clinical effects of sertraline (Hiemke and Hartter, 2000). Based on the
HtPC values, and the assumptions of the read-across hypothesis, then
the ER data in Table 2 would suggest that none of the pharmaceuticals
would have a therapeutic effect in ﬁsh. However, it should be noted
that the read-across hypothesis still has to be validated for many of
the SSRIs and other neuroactive pharmaceuticals investigated in this
study; that knowledge of the behavioural and other endpoints of their
action in ﬁsh remain incomplete; and the effects of SSRI exposure in
788 A. David et al. / Science of the Total Environment 621 (2018) 782–790concert with mixtures of other neuroactive substances remains uncer-
tain. A safety factor of 1000 for ER has been proposed to take into
consideration extrapolation of humans to animals, sensitivity differ-
ences, and extrapolation from mammalian to non-mammalian species
(Huggett et al., 2003). The ER ranges of ﬂuoxetine, sertraline,
norﬂuoxetine and amitriptyline fall within this safety factor indicating
that these compounds in ﬁsh should be prioritized for risk assessment
studies, especially if additive effects can be expected between SSRIs.
However, it should also be noted that the lower bound of ER ranges
for compound such as noramitriptyline, venlafaxine and nordiazepam
were below 1000, and therefore effects cannot be totally excluded for
these compounds if the same HtPC values are applicable to ﬁsh.3.4. Neurotransmitter concentrations in the brain of control and efﬂuent-
exposed ﬁsh
The concentrations of 4 neurotransmitters (serotonin, tryptophan,
acetylcholine and glutamate) were measured in the four brain regions
of male and female roach to investigate differences in brain chemistry
between control and efﬂuent-exposed ﬁsh. Serotonin and its precursor
tryptophan were selected since SSRIs act by inhibiting the serotonin
transporter in the pre-synaptic cell, which in turn leads to increased ex-
tracellular levels of serotonin in the synaptic cleft (Hiemke and Hartter,
2000). Likewise, the SNRI venlafaxine and the tricyclic antidepressants
act by blocking the serotonin transporter and could impact on serotonin
concentrations in the brain. Tricyclic antidepressants also have high af-
ﬁnity for antagonising the muscarinic acetylcholine receptors and
therefore act as potent anticholinergics (Snyder and Yamamura,
1977). Glutamate was also analysed as it is a precursor of gamma-Fig. 2. Serotonin concentrations (μg/g) in the telencephalon (A), hypothalamus (B), optic tectum
0.05. Each dot represents an individual ﬁsh within the treatment group, alongside the mean ±aminobutyric acid (GABA) and benzodiazepines are designed to alter
behaviour by binding to GABA receptors (Brodin et al., 2013).
The most abundant neurotransmitter found in the brain tissues of
control or efﬂuent exposed ﬁsh was glutamate (between 2.8–259 μg/g),
followed by tryptophan (3.2–57 μg/g), acetylcholine (0.22–6.3 μg/g)
and serotonin (0.04–1.1 μg/g). The concentrations of neurotransmitters
detected in the brain tissues of control or efﬂuent- exposed ﬁsh were
present at similar levels to that reported in the mammalian brain
(Gonzalez et al., 2011). Serotonin concentrations were also similar
with those reported for different regions of the brain in rainbow trout
(Sloman et al., 2005). Small but signiﬁcant increases in serotonin con-
centrations were observed in the hypothalamus (1.9 fold, p b 0.05)
and the telencephalon (1.5 fold, p b 0.01) in efﬂuent-exposed male
but not female roach (Fig. 2). A signiﬁcant decrease in glutamate (4
fold, p b 0.05) and acetylcholine concentrations (2.8 fold, p b 0.05)
was observed for the efﬂuent-exposed females in the hypothalamus
and a signiﬁcant glutamate increase (2.0–3.1 fold, p b 0.05) for the efﬂu-
ent-exposed males and female in the hindbrain (Figs. S3 and S4). A sig-
niﬁcant increase in tryptophan concentrations were also observed for
the efﬂuent-exposed males in the hypothalamus (1.7 fold, p b 0.05)
and the optic tectum (1.5 fold, p b 0.05) (Fig. S5). Our data suggests
that the disruption of neurotransmitter concentrations in the brain of
efﬂuent-exposed ﬁsh is sex dependent. However, an examination of
the data in Figs. 2 and S3–S5 reveals that the trend in responses is sim-
ilar in both sexes, and further workwith increased replication is needed
to determine whether there are gender speciﬁc responses to efﬂuent
exposure. It is not known whether the disruption of neurotransmitter
concentrations observed in our study would lead to changes in ﬁsh
behaviour and further studies would be required to determine this.
Monoaminergic systems play a crucial role in linking behaviour and(C) and hindbrain (D) of control and efﬂuent-exposedmale and female ﬁsh (n= 6). *p ≤
standard deviation of the replicates.
789A. David et al. / Science of the Total Environment 621 (2018) 782–790physiology in ﬁsh, and brain serotonin levels can inﬂuence food intake,
cognitive ability, locomotor activity and social behaviour in ﬁsh (Bisesi
et al., 2014; Sloman et al., 2005;Winberg et al., 1996). In addition, sero-
tonergic modulation in the hypothalamus similar to that observed in
this study has the potential to affect sex hormones and modulate
genes involved in reproductive function and behaviour in the brain of
female goldﬁsh (Mennigen et al., 2008; Prasad et al., 2015).
Further work is required to ascertain whether disruption of neuro-
transmitter levels caused by efﬂuent exposure is due solely to exposure
to thepharmaceuticalmixtures analysed in this study or a result of com-
bined exposure to other contaminants such as neurotoxic insecticides
which could potentially be present in the efﬂuent and contribute to
the alteration of ﬁsh neurotransmitter levels (Tuﬁ et al., 2016). Further-
more, our studywas based on exposure to an undiluted treated efﬂuent,
whichmay reﬂect the exposure conditions of aquatic organisms in some
countries where there is little or no dilution of the discharges into the
receiving waters during the summer period (David et al., 2013), but
would need to be conducted on diluted efﬂuents to be representative
of most ambient river environments.4. Conclusions
This study reports for the ﬁrst time that a highly complexmixture of
13 neuroactive pharmaceuticals, comprising SSRIs, SNRIs, atypical anti-
psychotics, tricyclic antidepressants and benzodiazepines, accumulates
in multiple brain regions of ﬁsh exposed to a treated WwTW efﬂuent.
Concentrations of all pharmaceuticals were below their respective
HtPCs however, disruptions in serotonin, glutamate, acetylcholine and
tryptophan concentrations were observed in different brain regions of
efﬂuent-exposed ﬁsh. Future risk assessment studies should be based
on understanding the effects of exposure to these complex chemical
mixtures on ﬁsh behaviour and physiology, particularly as future an-
thropogenic pressures are likely to result in increased pharmaceutical
exposures and ﬂuctuating hydrological conditions in river waters.Acknowledgment
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